Zobrazeno 1 - 10
of 10
pro vyhledávání: '"M Marieke Heisen"'
Autor:
Matthias Stoelzel, R. van Maanen, Arwin Ridder, Stefan A. Baeten, M Marieke Heisen, Elly A. Stolk, Zalmai Hakimi, B.G. Verheggen
Publikováno v:
Current Medical Research and Opinion. 32:787-796
We examined patient and treating physician (general practitioners, urologists, and [uro]gynecologists) preferences for oral pharmacotherapy (antimuscarinics and beta-3 adrenoceptor agonists) for overactive bladder to gain a deeper understanding of wh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae9c22861834b04486b9f6cdcce2411f
https://doi.org/10.1185/03007995.2016.1142959
https://doi.org/10.1185/03007995.2016.1142959
Autor:
B. M. J. Uitdehaag, J. van Wingerden, L. W. Wormhoudt, S. T. F. M. Frequin, M. A. Piena, M Marieke Heisen
Publikováno v:
Journal of Medical Economics, 21(10), 968-976. Taylor and Francis Ltd.
Piena, M A, Heisen, M, Wormhoudt, L W, Wingerden, J V, Frequin, S T F M & Uitdehaag, B M J 2018, ' Cost-minimization analysis of alemtuzumab compared to fingolimod and natalizumab for the treatment of active relapsing-remitting multiple sclerosis in the Netherlands ', Journal of Medical Economics, vol. 21, no. 10, pp. 968-976 . https://doi.org/10.1080/13696998.2018.1489255
Piena, M A, Heisen, M, Wormhoudt, L W, Wingerden, J V, Frequin, S T F M & Uitdehaag, B M J 2018, ' Cost-minimization analysis of alemtuzumab compared to fingolimod and natalizumab for the treatment of active relapsing-remitting multiple sclerosis in the Netherlands ', Journal of Medical Economics, vol. 21, no. 10, pp. 968-976 . https://doi.org/10.1080/13696998.2018.1489255
Aim: In active relapsing remitting multiple sclerosis (RRMS) patients requiring second-line treatment, the Dutch National Health Care Institute (ZiN) has not stated a preference for either alemtuzumab, fingolimod, or natalizumab. The aim was to give
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7257beec2a0f20c1c79a049154b6ee43
https://research.vumc.nl/en/publications/a12fd9af-5672-4520-8c2a-06c40d486459
https://research.vumc.nl/en/publications/a12fd9af-5672-4520-8c2a-06c40d486459
Publikováno v:
BMC Musculoskeletal Disorders
BMC Musculoskeletal Disorders, Vol 18, Iss 1, Pp 1-10 (2017)
BMC Musculoskeletal Disorders, Vol 18, Iss 1, Pp 1-10 (2017)
Background Since persistence to first biological disease modifying anti-rheumatic drugs (bDMARDs) is far from ideal in rheumatoid arthritis (RA) patients, many do receive a second and/or third bDMARD treatment. However, little is known about treatmen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6bc1e4d5f2d3c48287c7d99a71edfab
https://cronfa.swan.ac.uk/Record/cronfa38116/Download/0038116-02022018131137.pdf
https://cronfa.swan.ac.uk/Record/cronfa38116/Download/0038116-02022018131137.pdf
Publikováno v:
Journal of Medical Economics, 20(8):0046-RT.R1/1331912, 813-824. Taylor & Francis Ltd
Background: Until recently, standard treatment of venous thromboembolism (VTE) concerned a combination of short-term low-molecular-weight heparin (LMWH) and long-term vitamin-K antagonist (VKA). Risk of bleeding and the requirement for regular antico
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01db044d4974f4db886f1519ffaa6665
https://research.rug.nl/en/publications/4f4aac79-fd8c-4c26-b6cd-2409ac2901a4
https://research.rug.nl/en/publications/4f4aac79-fd8c-4c26-b6cd-2409ac2901a4
Publikováno v:
Rheumatology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fc9f3b05caec1a963c222925d002de2a
https://doi.org/10.1093/rheumatology/kew144.031
https://doi.org/10.1093/rheumatology/kew144.031
Autor:
Martijn Groot, W. S. van der Hel, M Marieke Heisen, BG Verheggen, S. T. F. M. Frequin, MJ Treur
Publikováno v:
Journal of Medical Economics. 15:1149-1158
To assess the costs of oral treatment with Gilenya® (fingolimod) compared to intravenous infusion of Tysabri® (natalizumab) in patients with relapsing-remitting multiple sclerosis (RRMS) in The Netherlands.A cost-minimization analysis was used to c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1bc0c8cbed6e9e1b34257db8dc52c93d
https://doi.org/10.3111/13696998.2012.707631
https://doi.org/10.3111/13696998.2012.707631
Autor:
Bart M. ter Haar Romeny, Natal A. W. van Riel, M Marieke Heisen, Xiaobing Fan, Johannes Buurman, Gregory S. Karczmar
Publikováno v:
Magnetic Resonance in Medicine. 63:811-816
Dynamic contrast-enhanced (DCE) MRI plays an essential role for cancer detection and characterization. Ideally, DCE-MRI data would be acquired with high spatial and high temporal resolution to fully exploit both the morphologic and kinetic informatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::51fae52d09ea35ab35651116ddc2ff88
https://doi.org/10.1002/mrm.22171
https://doi.org/10.1002/mrm.22171
Autor:
Klaas Nicolay, Raymond M. Schiffelers, Ewelina Kluza, Sophie Schmid, Gustav J. Strijkers, Bart M. ter Haar Romeny, M Marieke Heisen, Daisy W. J. van der Schaft, Gert Storm
Publikováno v:
Angiogenesis, 14(2), 143-153. Springer, Cham
Angiogenesis
Angiogenesis, 14(2), 143-153. Springer
Angiogenesis, 14(2), 143-153. Springer Netherlands
Angiogenesis
Angiogenesis, 14(2), 143-153. Springer
Angiogenesis, 14(2), 143-153. Springer Netherlands
Inflammation plays a prominent role in tumor growth. Anti-inflammatory drugs have therefore been proposed as anti-cancer therapeutics. In this study, we determined the anti-angiogenic activity of a single dose of liposomal prednisolone phosphate (PLP
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed10efe9d6bee260b312484a6bed2769
https://cris.maastrichtuniversity.nl/en/publications/b6b8a601-415c-4ec3-b472-5e4e4cec7557
https://cris.maastrichtuniversity.nl/en/publications/b6b8a601-415c-4ec3-b472-5e4e4cec7557
Autor:
Johannes Buurman, Xiaobing Fan, M Marieke Heisen, van Naw Natal Riel, ter Bm Bart Haar Romeny, Gregory S. Karczmar
Publikováno v:
Physics in Medicine and Biology, 55(16), 4871-4883. Institute of Physics
Pharmacokinetic modeling is a promising quantitative analysis technique for cancer diagnosis. However, diagnostic dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) of the breast is commonly performed with low temporal resolution. This li
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::077ad2fd0f3bf95d6dfe558ffced3e17
https://pubmed.ncbi.nlm.nih.gov/20679692
https://pubmed.ncbi.nlm.nih.gov/20679692
Publikováno v:
2010 IEEE International Symposium on Biomedical Imaging;14-17 april 2010, Rotterdam, Netherlands, 185-188
STARTPAGE=185;ENDPAGE=188;TITLE=2010 IEEE International Symposium on Biomedical Imaging;14-17 april 2010, Rotterdam, Netherlands
ISBI
STARTPAGE=185;ENDPAGE=188;TITLE=2010 IEEE International Symposium on Biomedical Imaging;14-17 april 2010, Rotterdam, Netherlands
ISBI
Pharmacokinetic modeling is increasingly used in DCE-MRI high risk breast cancer screening. Several models are available. The most common models are the standard and extended Tofts, the shutter-speed, and the Brix model. Each model and the meaning of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6f2919be4d7bbef2414d3e5936938f4
https://doi.org/10.1109/ISBI.2010.5490382
https://doi.org/10.1109/ISBI.2010.5490382